New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 19, 2014
08:11 EDTALKSAlkermes aripiprazole lauroxil data looks good, says Leerink
Leerink says the data Alkermes presented from its Phase III trial of aripiprazole lauroxil for treatment of schizophrenia at the American Society of Clinical Psychopharmacology Annual Meeting looks good. The firm expects FDA approval of AL in Q3 of 2015 following a 12-month regulatory review. It maintains an Outperform rating on the stock with a $66 price target.
News For ALKS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 25, 2015
08:30 EDTALKSAlkermes price target raised to $79 from $75 at Leerink
Leerink raised its price target for Alkermes shares to $79 to reflect probability-of-success weighted ALKS 8700 in multiple sclerosis revenue. The firm views the company's Q4 results as strong, but notes its 2015 outlook missed consensus due to higher than expected operating expenses. Leerink says the 2015 guidance reflects Alkermes' maturing pipeline. It keeps an Outperform rating on the stock.
06:19 EDTALKSAlkermes pipeline eases loss of pain program, says Citigroup
Citigroup says Alkermes' pipeline programs and the continued growth of its base business help moderate the disappointment of the discontinuation of novel pain program ALKS-7106. Citi lowered its price target for Alkermes shares to $83 from $85 and keeps a Buy rating on the stock.
05:57 EDTALKSUBS says remain on sidelines with respect to Alkermes
Subscribe for More Information
February 24, 2015
10:06 EDTALKSHigh option volume stocks
High option volume stocks: CHGG LBTYK SMH RCAP NGLS OTEX TERP CNC ALKS AMT
08:56 EDTALKSOn The Fly: Pre-market Movers
Subscribe for More Information
08:54 EDTALKSAlkermes 7106 halt overshadows Q4 beat, says Credit Suisse
Subscribe for More Information
07:06 EDTALKSAlkermes sees FY15 adjusted EPS 27c-40c, consensus 20c
Subscribe for More Information
07:03 EDTALKSAlkermes reports Q4 EPS 11c, consensus 4c
Subscribe for More Information
07:01 EDTALKSAlkermes announces phase 1 results for ALKS 7106, will not proceed to phase 2
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use